DK3144002T3 - Kontrolmiddel til gm-csf-producerende t-celler og th1/th2-immunbalanceregulator - Google Patents

Kontrolmiddel til gm-csf-producerende t-celler og th1/th2-immunbalanceregulator Download PDF

Info

Publication number
DK3144002T3
DK3144002T3 DK15792520.7T DK15792520T DK3144002T3 DK 3144002 T3 DK3144002 T3 DK 3144002T3 DK 15792520 T DK15792520 T DK 15792520T DK 3144002 T3 DK3144002 T3 DK 3144002T3
Authority
DK
Denmark
Prior art keywords
csf
cells
producing
control agent
balance regulator
Prior art date
Application number
DK15792520.7T
Other languages
English (en)
Inventor
Takashi Yamamura
Daisuke Noto
Sachiko Miyake
Original Assignee
Nat Center Neurology & Psychiatry
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Center Neurology & Psychiatry filed Critical Nat Center Neurology & Psychiatry
Application granted granted Critical
Publication of DK3144002T3 publication Critical patent/DK3144002T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK15792520.7T 2013-12-19 2015-04-28 Kontrolmiddel til gm-csf-producerende t-celler og th1/th2-immunbalanceregulator DK3144002T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013262876 2013-12-19
JP2014099587A JP6202339B2 (ja) 2013-12-19 2014-05-13 ＧＭ−ＣＳＦ産生Ｔ細胞制御剤、及びＴｈ１／Ｔｈ２免疫バランス調節剤
PCT/JP2015/062854 WO2015174278A1 (ja) 2013-12-19 2015-04-28 ＧＭ－ＣＳＦ産生Ｔ細胞制御剤、及びＴｈ１／Ｔｈ２免疫バランス調節剤

Publications (1)

Publication Number Publication Date
DK3144002T3 true DK3144002T3 (da) 2023-08-14

Family

ID=53766894

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15792520.7T DK3144002T3 (da) 2013-12-19 2015-04-28 Kontrolmiddel til gm-csf-producerende t-celler og th1/th2-immunbalanceregulator

Country Status (8)

Country Link
US (1) US20170151270A1 (da)
EP (1) EP3144002B1 (da)
JP (2) JP6202339B2 (da)
DK (1) DK3144002T3 (da)
ES (1) ES2952391T3 (da)
FI (1) FI3144002T3 (da)
PL (1) PL3144002T3 (da)
WO (1) WO2015174278A1 (da)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021008263A2 (pt) * 2018-10-31 2021-08-10 Humanigen, Inc. materiais e métodos para tratamento de câncer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004131481A (ja) * 1997-04-10 2004-04-30 Kirin Brewery Co Ltd α−グリコシルセラミドを含有するＮＫＴ細胞活性化剤
CA2459482C (en) * 2001-08-16 2010-09-28 Daiichi Suntory Pharma Co., Ltd. Novel glycolipid and medicine for autoimmune disease containing the same as active ingredient
CA2683681A1 (en) * 2007-04-13 2008-10-23 Academia Sinica Alpha-galactosyl ceramide analogs and their use as immunotherapies
DK2344540T3 (da) * 2008-10-02 2018-01-29 Aptevo Res & Development Llc Cd86-antagonist multimål bindingsproteiner
CN109876138A (zh) * 2011-05-03 2019-06-14 免疫创新治疗有限公司 利用免疫疗法诱导il-12
CN104797711B (zh) * 2012-09-12 2018-09-21 株式会社癌免疫研究所 抗原特异性辅助性t细胞受体基因
US20170027973A1 (en) * 2014-04-11 2017-02-02 London Health Sciences Centre Research Inc. Modularion of invariant natural killer t cells in the treatment of sepsis

Also Published As

Publication number Publication date
JP6400166B2 (ja) 2018-10-03
EP3144002B1 (en) 2023-05-17
WO2015174278A1 (ja) 2015-11-19
JP6202339B2 (ja) 2017-09-27
FI3144002T3 (fi) 2023-08-04
JP2018009011A (ja) 2018-01-18
PL3144002T3 (pl) 2023-10-02
EP3144002A1 (en) 2017-03-22
EP3144002A4 (en) 2018-02-07
JP2015134742A (ja) 2015-07-27
US20170151270A1 (en) 2017-06-01
ES2952391T3 (es) 2023-10-31

Similar Documents

Publication Publication Date Title
IL276106A (en) Garp-binding proteins and their uses
SG11201803493UA (en) Genetically modified cells and uses thereof
DK3043784T3 (da) Arylethere og anvendelser deraf
SG11201604906QA (en) Cloud-based transactions methods and systems
DK3089994T3 (da) Fabs-in-tandem-immunglobulin og anvendelser deraf
DK2970460T3 (da) Anti-IL-33-antistoffer og anvendelser deraf
EP2997538A4 (en) DETECTION OF LINGUISTIC SKILLS IN SOCIAL NETWORK APPLICATIONS
DK3079719T3 (da) ANTI-SIGLEC-8-antistoffer og fremgangsmåder til anvendelse deraf
DK3035801T3 (da) Vækstregulatorkoncentrat og anvendelse deraf
DK3065771T3 (da) Fremgangsmåder og sammensætninger til vedvarende immunterapi
GB201404224D0 (en) Instruction emulation processors methods and systems
GB201709240D0 (en) Rapid response with direct connect for emergency responders
DK3086807T3 (da) Antistoffer og fremgangsmåder til anvendelse
DK2962100T3 (da) Tuberkulosebiomarkører og anvendelser deraf
GB201313712D0 (en) Optimizing emergency resources in case of disaster
DK2995025T3 (da) Fremgangsmåder og indretninger til signalering i dynamiske tidsdelte duplex-systemer
SG11201510243QA (en) Method of control of persons and application to the inspection of persons
DK2964767T3 (da) Toksingener og fremgangsmåder til anvendelse deraf
IL259202A (en) Modified immune cells and their use
PL3066434T3 (pl) Waga i jej konstrukcja wiatrooszczelna
GB201303182D0 (en) Rebreather system and components
GB201412043D0 (en) Cell positioning and analysis device
DK2994150T3 (da) Probiotika og fremgangsmåde til anvendelse
GB201602019D0 (en) Method and load analysis for multi-off-center toools
PL2962296T3 (pl) Analiza języka oparta na doborze słów i urządzenie do analizy języka